Clinical trials are currently testing the combination of a Raf-MEK inhibitor (avutometinib) with a FAKi (defactinib) for KRAS-mutated NSCLC (25) and LGSOC (26). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.